表紙
市場調查報告書

日本腦炎疫苗的全球市場:2019年∼2023年

Global Japanese Encephalitis Vaccines Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 881683
出版日期 內容資訊 英文 131 Pages
訂單完成後即時交付
價格
Back to Top
日本腦炎疫苗的全球市場:2019年∼2023年 Global Japanese Encephalitis Vaccines Market 2019-2023
出版日期: 2019年06月26日內容資訊: 英文 131 Pages
簡介

為了預防日本腦炎的高風險,全國免疫計劃涉及大規模疫苗接種。該計劃導致疫苗接種劑量的增加。在國家免疫計劃中納入針對日本腦炎的疫苗接種將導致全球日本腦炎疫苗市場在預測期內以近9%的年複合成長率擴大。

本報告提供全球日本腦炎疫苗市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 *市場區隔:各類型

  • 市場區隔:各類型
  • 比較:各類型市場規模及預測(2018年∼2023年)
  • 不活化疫苗
  • 重組疫苗
  • 弱毒化活病毒疫苗
  • 市場機會:各類型

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 亞洲
  • 其他地區
  • 歐洲
  • 北美
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 新的疫苗技術
  • 金磚五國對研究強大投資
  • 亞洲的入境旅遊增加

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭模式

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Bharat Biotech Ltd.
  • Biological E. Ltd.
  • Green Cross Corp.
  • Sanofi
  • Valneva SE

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31555

About this market

Japanese encephalitis is an inflammation in the brain, which is usually asymptomatic and is caused by a mosquito-borne flavivirus. Technavio's Japanese encephalitis vaccines market analysis considers sales from different type, including inactivated vaccines, recombinant vaccines, and live attenuated vaccines. Our analysis also considers the sales of Japanese encephalitis vaccines in Asia, Europe, North America, and ROW. In 2018, the inactivated vaccines segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the increasing number of choices and wide treatment options of the segment will play a significant role in the inactivated vaccines segment to maintain its market position. Also, our global Japanese encephalitis vaccines market report looks at factors such as the inclusion in national immunization plan, strategic alliances, and a growing number of awareness campaigns. However, demand-supply imbalance, geographic concentration, and weak pipeline may hamper the growth of the Japanese encephalitis vaccines industry over the forecast period.

Overview

Inclusion in national immunization plan

National immunization plans to prevent the high risk of Japanese encephalitis involves mass vaccinations. This plan results in an increased procurement of vaccination doses. The inclusion of vaccination against Japanese encephalitis in national immunization plans will lead to the expansion of the global Japanese encephalitis vaccines market at a CAGR of almost 9% during the forecast period.

Strong investments from BRICS in research

With the growing incidence of Japanese encephalitis, BRICS is developing vaccines against the indication. Pharmaceutical companies are supporting the development of these vaccines by investing in research and developmental activities. The presence of strong manufacturing facilities in BRICS countries is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global Japanese encephalitis vaccines market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of a few major players, the global Japanese encephalitis vaccines market is concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Japanese encephalitis vaccines manufacturers, that include Bharat Biotech Ltd., Biological E. Ltd., Green Cross Corp., Sanofi, and Valneva SE.

Also, the Japanese encephalitis vaccines market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06:* MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Inactivated vaccines - Market size and forecast 2018-2023
  • Recombinant vaccines - Market size and forecast 2018-2023
  • Live attenuated vaccines - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • North America - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Novel vaccine technology
  • Strong investments from BRICS in research
  • Growing inbound travel to Asia

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bharat Biotech Ltd.
  • Biological E. Ltd.
  • Green Cross Corp.
  • Sanofi
  • Valneva SE

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Type - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by type
  • Exhibit 20: Inactivated vaccines - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Inactivated vaccines - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Recombinant vaccines - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Recombinant vaccines - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Live attenuated vaccines - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Live attenuated vaccines - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Market opportunity by type
  • Exhibit 27: Customer landscape
  • Exhibit 28: Market share by geography 2018-2023 (%)
  • Exhibit 29: Geographic comparison
  • Exhibit 30: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Top 3 countries in Asia
  • Exhibit 33: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in ROW
  • Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in Europe
  • Exhibit 39: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 40: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 41: Top 3 countries in North America
  • Exhibit 42: Key leading countries
  • Exhibit 43: Market opportunity
  • Exhibit 44: Impact of drivers and challenges
  • Exhibit 45: Vendor landscape
  • Exhibit 46: Landscape disruption
  • Exhibit 47: Vendors covered
  • Exhibit 48: Vendor classification
  • Exhibit 49: Market positioning of vendors
  • Exhibit 50: Bharat Biotech Ltd. - Vendor overview
  • Exhibit 51: Bharat Biotech Ltd. - Business segments
  • Exhibit 52: Bharat Biotech Ltd. - Organizational developments
  • Exhibit 53: Bharat Biotech Ltd. - Key offerings
  • Exhibit 54: Bharat Biotech Ltd. - Key customers
  • Exhibit 55: Biological E. Ltd. - Vendor overview
  • Exhibit 56: Biological E. Ltd. - Business segments
  • Exhibit 57: Biological E. Ltd. - Organizational developments
  • Exhibit 58: Biological E. Ltd. - Key offerings
  • Exhibit 59: Biological E. Ltd. - Key customers
  • Exhibit 60: Green Cross Corp. - Vendor overview
  • Exhibit 61: Green Cross Corp. - Business segments
  • Exhibit 62: Green Cross Corp. - Organizational developments
  • Exhibit 63: Green Cross Corp. - Geographic focus
  • Exhibit 64: Green Cross Corp. - Segment focus
  • Exhibit 65: Green Cross Corp. - Key offerings
  • Exhibit 66: Green Cross Corp. - Key customers
  • Exhibit 67: Sanofi - Vendor overview
  • Exhibit 68: Sanofi - Business segments
  • Exhibit 69: Sanofi - Organizational developments
  • Exhibit 70: Sanofi - Geographic focus
  • Exhibit 71: Sanofi - Segment focus
  • Exhibit 72: Sanofi - Key offerings
  • Exhibit 73: Sanofi - Key customers
  • Exhibit 74: Valneva SE - Vendor overview
  • Exhibit 75: Valneva SE - Business segments
  • Exhibit 76: Valneva SE - Organizational developments
  • Exhibit 77: Valneva SE - Geographic focus
  • Exhibit 78: Valneva SE - Segment focus
  • Exhibit 79: Valneva SE - Key offerings
  • Exhibit 80: Valneva SE - Key customers
  • Exhibit 81: Validation techniques employed for market sizing
  • Exhibit 82: Definition of market positioning of vendors
Back to Top